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Rationale & Objective: Research on pediatric
kidney replacement therapy (KRT) has primarily
focused on Europe and North America. In this
study, we describe the mortality risk of children
treated with maintenance peritoneal dialysis
(MPD) in different parts of the world and characterize the associated demographic and macroeconomic factors.
Study Design: Prospective cohort study.
Setting & Participants: Patients younger than 19
years at inclusion into the International Pediatric
Peritoneal Dialysis Network registry, who initiated
MPD between 1996 and 2017.
Exposure: Region as primary exposure (Asia,
Western Europe, Eastern Europe, Latin America,
North America, and Oceania). Other demographic, clinical, and macroeconomic (4 income groups based on gross national income)
factors also were studied.
Outcome: All-cause MPD mortality.
Analytical Approach: Patients were observed for
3 years, and the mortality rates in different

M

regions and income groups were calculated.
Cause-speciﬁc hazards models with random
effects were ﬁt to calculate the proportional
change in variance for factors that could explain
variation in mortality rates.
Results: A total of 2,956 patients with a median
age of 7.8 years at the start of KRT were included.
After 3 years, the overall probability of death was
5%, ranging from 2% in North America to 9% in
Eastern Europe. Mortality rates were higher in
low-income countries than in high-income
countries. Income category explained 50.1% of
the variance in mortality risk between regions.
Other explanatory factors included peritoneal
dialysis modality at start (22.5%) and body
mass index (11.1%).
Limitations: The interpretation of interregional
survival differences as found in this study may be
hampered by selection bias.
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Conclusions: This study shows that the overall 3year patient survival on pediatric MPD is high, and
that country income is associated with patient
survival.

aintenance peritoneal dialysis (MPD) is a wellestablished treatment option for children with kidney failure.1 Usually performed at home by the adult
caregivers, MPD is the preferred dialysis modality in
children due to its applicability across the entire pediatric
age range and compatibility with schooling and social life.
Notwithstanding its successful implementation in the pediatric population, MPD remains a challenging therapy
subject to significant patient morbidity and mortality.2,3
Population-based registries in Europe and North
America have provided information on patient survival
among children undergoing dialysis and kidney transplantation.4,5 Although the survival rates appear to have
improved over the past 3 decades, annual mortality rates
for children on dialysis are at least 30 times higher than
those of the general pediatric population, with 5-year
patient survival around 84% and 90% in North American
and European children, respectively.3,4
Young patient age, late referral to a pediatric nephrologist, glomerular disease, the presence of comorbidities,
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low socioeconomic status, and reduced access to kidney
transplantation have been identified as potential mortality
risk factors for children undergoing maintenance dialysis.3,6-10 In addition, macroeconomic factors appear to
play a crucial role in the survival of children on kidney
replacement therapy (KRT). A recent comparison of children’s mortality rates across 32 European countries
revealed an inverse association between country-specific
mortality rates and the gross domestic product per
capita.11
While epidemiological research into pediatric KRT has
largely focused on Europe and North America, the majority (62.5%) of children undergoing maintenance dialysis live in other parts of the globe.12 As the variation in
environmental, ethnic, cultural, political, and macroeconomic factors is larger on the global scale, this may impact
patient survival through the timing of KRT initiation, the
criteria of patient selection for KRT, the choice of dialysis
modality, dialysis treatment quality and treatment times,
and the prevalence of non–dialysis-related risk factors.
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PLAIN-LANGUAGE SUMMARY
So far, research on children who are treated with dialysis or have received a kidney transplant has focused on
Europe and North America. In this study, we describe
the mortality risk of children on maintenance peritoneal
dialysis in different parts of the world and assess which
factors are associated with patient survival. We included
2,956 patients younger than 19 years from the International Pediatric Peritoneal Dialysis Network who
started maintenance peritoneal dialysis between 1996
and 2017. After 3 years, the overall probability of death
was 5%, ranging from 2% in North America to 9% in
Eastern Europe. Mortality was higher in low-income
countries than in high-income countries. This study
shows that the overall patient survival on maintenance
peritoneal dialysis is high in children, and that country
income is associated with patient survival.

For more than a decade, the International Pediatric
Peritoneal Dialysis Network (IPPN) Registry has been collecting patient outcome data along with comprehensive
clinical, biochemical, and treatment information from a
large number of children undergoing MPD around the
globe.13 Earlier research based on this database identified
associations of patient survival with clinical and laboratory
findings10,14 and with macroeconomic factors.15 In the
current study, we used IPPN data to describe (1) the current
global and regional mortality risk of children treated with
MPD, (2) the main causes of death, and (3) the macroeconomic factors that are associated with mortality risk and/
or the distribution of death causes around the globe.
Methods
Study Population
The IPPN Registry collects prospective data from pediatric
peritoneal dialysis (PD) centers worldwide. The participating centers are asked to enroll all their incident and
prevalent MPD patients and to enter their data every 6
months until MPD is stopped. Data input to the IPPN
Registry is voluntary and performed exclusively via an
internet-based platform. Data entries are automatically
checked for plausibility and completeness, and data protection is ensured by pseudonymized data input.
For the current study, we included all patients who
were younger than 19 years at inclusion in the IPPN
Registry and who started treatment with MPD between
1996 and 2017. The IPPN Registry’s protocol was
approved by the ethics committees/institutional review
boards as required at each participating center. Written
parental consent and, whenever appropriate, assent from
patients was obtained.
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Data Collection and Deﬁnitions
For the current study, the primary exposure of interest was
region. We therefore divided the study cohort into regions
based on the location of the center: Asia, Europe, Latin
America, North America, and Oceania. An overview of the
countries per region participating in the IPPN Registry is
provided in Table S1. Because previous studies showed that
there is a large variation within Europe, we subdivided
Europe into Eastern and Western Europe.11
The economic wealth of each participating country was
classified by the per-capita gross national income (GNI) in
2016 based on purchasing power parity converted to international dollars, using the tables published by the World
Bank. An international dollar has the same purchasing power over GNI as a US dollar has in the United States. The
majority of the countries contributing data to the IPPN
Registry would be considered “high-income” countries
according to the official criteria of the World Bank (GNI >
$12,276).16 To differentiate group effects associated with
relative economic wealth in the present analysis, we readjusted the partition values, dividing countries into 4 income
groups based on the GNI distribution within the IPPN
cohort: low-income (<$12,000), lower-middle income
($12,000 to <$16,000), upper-middle income ($16,000
to <$45,000), and high-income ($45,000 or more).
For each patient, we extracted data on date of birth, sex,
time on KRT before current episode of MPD, primary
kidney disorder, the presence of comorbidities at the start
of the current treatment, and events including death and
cause of death, changes in treatment modality, and other
reasons for discontinuation of MPD (ie, recovery of native
kidney function or loss to follow-up assessment).
The presence of the following comorbidities was
recorded: cognitive dysfunction, motor dysfunction,
ocular dysfunction, hearing dysfunction, cardiac abnormality, pulmonary abnormality, osseous abnormality, or
other abnormality. Primary kidney disorders were grouped
into 5 categories: (1) congenital anomalies of the kidney
and urinary tract (CAKUT) and other ciliopathies, (2)
glomerulopathies, (3) chronic kidney disease after acute
kidney injury, (4) metabolic disease, and (5) other/
miscellaneous disease. Age at the start of MPD was grouped
into 4 age categories: 0-4, 5-9, 10-14, and 15-19 years.
Body mass index (BMI) z-scores at entry in the registry
were calculated using WHO Child Growth Standards for
children up to 2 years and CDC 2000 charts for children
aged 2 to 20 years and grouped into 3 categories: underweight (<5th percentile), normal weight (5th–85th
percentile), and overweight (>85th percentile).17 Causes
of death were classified as infection, malignancy, pulmonary edema, congestive heart failure, recurrence of disease,
noninfectious dialysis-related complications, and other/
miscellaneous disease. These causes were grouped into 4
categories: infection related, dialysis related, cardiovascular
related (including pulmonary edema), and other death
causes.
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Statistical Analyses
Patient characteristics at inclusion in the IPPN Registry
were expressed as median values with interquartile range
for all numerical variables and as proportions for all categorical variables. Differences between regions in numerical variables were assessed using Kruskal-Wallis tests and
differences in proportions using χ 2 tests.
The primary outcome studied was all-cause mortality
on MPD, expressed as crude and adjusted (for age and
sex) mortality rates per 100 patient-years; the primary
exposures studied were region and GNI. Death cause–,
region-, and GNI-specific mortality rates were also
calculated. Differences in mortality rates between groups
were tested using generalized linear models with a
Poisson distribution (SAS Proc Genmod, dist=Poisson).
These models also yielded the 95% confidence intervals
around the rates.
To describe the probabilities pertaining to survival and
modality switches in the overall population and per region, the cumulative incidence competing risks (CICR)
method is preferred because it accounts for the effect of
competing events.18 A competing event is defined as an
event that either hinders the observation of the event of
interest or modifies the chance that this event occurs. We
were interested in death on MPD, so switching to a
different treatment modality (ie, hemodialysis [HD] or
kidney transplantation) was considered a competing event.
Patients were observed from the start of MPD until death,
until switching to another treatment modality, or to the
end of 3 years, whichever came first. For the sake of
comparison with previous literature, we also included a
Kaplan-Meier analysis.
Because variation in mortality rates could be attributed both to country-specific factors and to differences
in patient characteristics, we used a cause-specific hazards model with random effects in which the baseline
risk of mortality of a region is modeled as the random
effect, and the effect of macroeconomic or patient factors is allowed to vary by region. The random effect for
each region represents the degree of deviation in mortality risk from the overall mortality risk. The heterogeneity in mortality risk is reflected by the variance
estimate of the random effect. The variance estimate in
the baseline model represents the variation in mortality
risk per region. Adding an explanatory factor to the
model, on either country or patient level, allows the
variance estimate to be adjusted for this factor. The
proportional change in variance (PCV) after addition of
this explanatory factor to the baseline model therefore
allows examination of its effect on the variation in
mortality risk between regions. The PCV is calculated by
subtracting the adjusted variance from the baseline
variance and dividing by the baseline variance. Negative
values for PCV are explanatory for the variance (ie, the
variance between regions is reduced) whereas positive
values indicate an increase in variance.11,19
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Covariates were only included in the multivariable
models if they satisfied all 3 criteria for confounding. To
be a potential confounder, a variable (1) must be a risk
factor for the outcome (death), (2) must be associated
with the exposure, and (3) must not be an effect of the
exposure; this means that the variable should not be in the
causal pathway.20 For the primary exposure (region), no
confounders could be identified, as is illustrated in the
directed acyclic graph in Figure S1. Next, we created
separate multivariate models to assess the associations of
GNI, age, sex, primary kidney disorder, BMI, number of
comorbidities, modality choice, and KRT vintage (in
months) with all-cause mortality on MPD. Again, only
those variables that fulfilled the criteria for confounding
were included in those models.
Data were analyzed using SAS version 9.4 (SAS Institute,
Cary, NC). P < 0.05 was considered statistically significant.

Results
Cohort Characteristics
A total of 2,956 patients were included. Table 1 displays
the variation in annual GNI in US dollars per capita and
patient characteristics between regions. Most Asian
countries (56.4%) fell in the lowest GNI quartile
whereas Latin American countries tended to have a
slightly higher GNI. In Western Europe, all countries fell
in the higher GNI quartiles whereas Eastern European
countries clustered within the middle quartiles. In North
America all countries were classified as having a high
GNI.
The median age at initiation of KRT was 7.8 years and
varied between 4.9 years in Western Europe and 9.3
years in Asia. The median age at inclusion in the IPPN
was 8.3 years, ranging from 5.3 in Western Europe to
9.8 in North America. In general, patients treated in
Europe were younger than in Asia and North America
(P < 0.001).
The most frequent primary kidney disorder was CAKUT
and other ciliopathies (46.2%) followed by glomerulopathies (27.6%). North America and Eastern Europe
had higher percentages of patients with a defined syndrome (17.7% and 17.6%, respectively) compared with
other regions. Confirmed genetic disorders were significantly less common in Latin America (4.1% vs 12.4%
overall). The most frequent comorbidities were cardiac
abnormalities (14.1%), cognitive dysfunction (13.8%),
and motor dysfunction (11.7%), with markedly higher
percentages of all comorbidities except for hearing
dysfunction reported in North America (P < 0.001).
Approximately one-third of the patients had received
KRT before starting their current MPD treatment, of
whom 20.1% had received a transplant and 79.9% had
undergone dialysis treatment (HD, previous PD, or both).
The time on KRT before inclusion in the IPPN Registry
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Characteristics
Macroeconomics
Income classa
<$12,000
$12,000-15,829
$15,830-45,790
>$45,790
GNI, ×$1,000b

Total Cohort
(N = 2,956)

Asia
(n = 596)

Western Europe
(n = 671)

Eastern Europe
(n = 667)

Latin America
(n = 584)

North America
(n = 389)

Oceania
(n = 49)

25.4%
28.5%
21.1%
25.0%
14.3 [12.0-45.8]

56.4%
31.5%
7.5%
4.6%
12.0 [8.0-12.0]

0%
0%
55.0%
45.0%
43.7 [40.7-45.8]

6.4%
64.3%
29.3%
0%
13.3 [9.5-18.3]

33.2%
58.9%
7.9%
0%
12.3 [9.9-14.3]

0%
0%
0%
100%
56.3 [56.3-56.3]

0%
0%
92.5%
7.5%
40.3 [40.340.3]

56.3%
9.3 [5.2-12.9]

59.5%
4.9 [0.7-11.8]

55.3%
7.2 [1.8-12.7]

53.8%
8.8 [3.4-12.7]

54.9%
8.8 [1.0-14.1]

46.9%
6.4 [1.5-11.1] <0.001

9.5 [5.2-13.0]

5.3 [0.8-12.5]

7.6 [1.9-12.9]

9.3 [3.7-13.1]

9.8 [1.3-14.6]

28.4%
37.7%
31.5%
12.4%

48.1%
18.2%
20.0%
13.7%

39.2%
21.5%
23.5%
15.8%

29.7%
24.9%
37.9%
7.5%

36.5%
13.9%
27.7%
22.4%

7.0 [1.6-11.9] <0.001
<0.001
38.8%
26.5%
30.6%
4.1%

34.4%
36.6%
4.5%
0.8%
23.3%
8.8%
13.9%

49.0%
27.1%
8.8%
2.1%
13.0%
15.8%
23.5%

46.9%
28.0%
8.7%
1.9%
14.5%
17.6%
15.4%

51.2%
22.6%
7.2%
1.2%
17.8%
7.9%
4.1%

39.2%
28.5%
5.6%
0.3%
26.4%
17.7%
12.6%

36.7%
30.6%
8.2%
2.0%
22.4%
6.1%
14.3%

<0.001
<0.001

13.7%
8.0%
5.0%
8.0%
5.7%
2.9%
2.6%
13.3%

15.5%
19.5%
15.9%
9.7%
14.8%
9.8%
5.2%
16.2%

14.1%
14.4%
12.9%
16.7%
8.7%
4.5%
4.8%
26.7%

10.8%
11.6%
10.1%
9.8%
5.3%
1.7%
4.1%
12.0%

24.9%
16.2%
16.2%
20.8%
12.1%
11.3%
5.9%
27.9%

16.3%
12.2%
10.2%
4.1%
8.2%
2.0%
6.1%
8.2%

<0.001
<0.001
<0.0001
<0.0001
<0.001
<0.001
0.1
<0.001

P
<0.001

Patient Characteristics
Male sex
55.8%
Age at initiation of KRT,
7.8 [1.9-12.8]
years
Age at inclusion, years
8.3 [2.2-13.1]
Age at inclusion
0-4 years
35.5%
5-9 years
22.5%
10-14 years
28.7%
15-19 years
13.2%
Primary Kidney Disorder
Category
CAKUT and ciliopathies 46.2%
Glomerulopathies
27.6%
Post-AKI CKD
6.6%
Metabolic diseases
1.8%
Other
17.9%
Deﬁned syndrome
12.4%
Conﬁrmed genetic disorder 14.2%
Comorbidities
Cardiac abnormality
14.1%
Cognitive dysfunction
13.8%
Motor dysfunction
11.7%
Osseous abnormality
11.3%
Ocular dysfunction
9.8%
Pulmonary abnormality
5.3%
Hearing dysfunction
4.4%
Other abnormality
16.8%

<0.001

<0.001

(Continued)
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Table 1. Patient Characteristics at Inclusion in the IPPN Registry
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Values for continuous variables given as median [interquartile range]. Abbreviations: AKI, acute kidney injury; APD, automated peritoneal dialysis; BSA, body surface area; CAKUT, congenital abnormalities of the kidney and urinary
tract; CAPD, continuous ambulatory peritoneal dialysis; CKD, chronic kidney disease; GNI, gross national income; HD, hemodialysis; IPPN, International Pediatric Peritoneal Dialysis Network; KRT, kidney replacement therapy; PD,
peritoneal dialysis; Tx, transplantation.
a
Percentage of countries, US$ per capita.
b
US$ per capita, Atlas method.
c
HD and/or PD.

<0.001
2.0%
95.9%
2.0%
11.5%
87.3%
1.0%
24.7%
74.6%
0.3%

20.9%
76.9%
1.3%

35.6%
64.4%
0.0%

2.6%
97.4%
0.0%

<0.001
0.05
<0.001
0.0 [0.0-0.0]
16.3%
8.2%
0.0 [0.0-3.0]
39.1%
10.8%
0.0 [0.0-1.0]
25.9%
8.0%
0.0 [0.0-0.0]
20.7%
7.7%
0.0 [0.0-1.0]
31.4%
2.9%

0.0 [0.0-0.0]
21.2%
5.8%

400 [45-645] <0.001
0 [0-500]
614 [200-1,200]
300 [10-800]
300 [50-700]

600 [100–1,200]

Western Europe
(n = 671)
Asia
(n = 596)

Total Cohort
Characteristics
(N = 2,956)
Treatment at Registry Entry
Residual diuresis (mL/m2 400 [50-1,000]
BSA)
KRT vintage, months
0.0 [0.0-1.0]
Dialysis before inclusionc 26.2%
Tx before inclusion
6.6%
PD Modality at Registry Entry
CAPD
23.5%
APD
75.7%
Other
0.6%

Table 1 (Cont'd). Patient Characteristics at Inclusion in the IPPN Registry

Eastern Europe
(n = 667)

Latin America
(n = 584)

North America
(n = 389)

Oceania
(n = 49)

P
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was very short (median 3.0 [interquartile range,
1.0–22.0] months). Upon entry to the registry, the majority were treated with automated PD (75.7%), followed
by continuous ambulatory PD (23.5%), and other PD
treatment (1.6%). The distribution of PD modalities
differed significantly among regions (P < 0.001). The
percentage of automated PD patients was highest in
North America (95.1%).
Patient Survival
Because of the limited number of patients (n = 49), Oceania was excluded from the survival analyses. The median
follow-up duration in the IPPN Registry was 1.68 [IQR,
0.8-3.0] years. MPD was stopped during the follow-up
period in 1,969 patients, of whom 177 (9%) died.
Other common causes for the follow-up period to end
were kidney transplantation (64.6%), switch to HD (for
several reasons, 9.1%), and loss to follow-up assessment
(6.5%).
All-cause MPD mortality rates per 100 patient-years per
region are displayed in Figure 1. The mortality rate in
North America was significantly lower than the mortality
rates in other regions. Mortality rates adjusted for region
were highest in low-income countries, followed by the
lower-middle-income countries (Fig 1).
When stratifying mortality rates according to region
and cause of death, infection-related death was highest in
low-income countries, and particularly in Eastern Europe
and Latin America (Fig 2). Cardiovascular-related death
declined with increasing GNI. Similarly, death due to
dialysis-related complications was highest in the lower
GNI classes, but was also slightly elevated in the highest
income group.
The CICR analysis (Fig 3A) shows that after 3 years,
the probability of death in the overall cohort was 5%.
The probability of switching to HD as a result of technique failure was 6%. Almost half of the children
received a kidney allograft (43%), and the remaining
46% were still alive on MPD. When we repeated this
analysis including only the patients incident on MPD, this
did not change our findings. Figure 3B-F displays the
region-specific CICR probabilities, with the lowest
probability of death in North America (2%) and the
highest in Eastern Europe (9%).
CICR analysis was also performed by GNI quartile
(Fig 4). It showed that after 3 years of follow-up assessment patients in countries with a low GNI tended to have a
higher mortality risk and a lower probability of receiving a
kidney transplant.
Because there was substantial variation in patient survival by region, we used cause-specific hazards models
with random effects to assess whether the differences in
other factors could explain this variation. We built separate
statistical models for these factors, which are specified in
Table 2. Also the PCV per factor is displayed in Table 2.
Country differences in GNI explained 50.1%, choice of
modality explained 22.5%, and BMI explained 11.1% of
AJKD Vol 78 | Iss 3 | September 2021
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Eastern Europe
Asia
Oceania
Lan America
Western Europe
North America
0

1

2

3

4

5

6

7

8

9

8

9

High-income
High middle-income

Standardized for Connent

Low middle-income
Low income
0

1

2

3
4
5
6
Mortality rate per 100 paent-years

7

Figure 1. All-cause maintenance peritoneal dialysis (MPD) mortality rates per 100 patient-years with 95% conﬁdence intervals per
region and per gross national income (GNI) category. GNI category based on data from the World Bank.

the variance among regions. Other minor explanatory
factors included KRT vintage (9.3%) and sex (2.4%).
Primary kidney disorder, age group, and number of
comorbidities only increased the variance between regions

(2.1%, 32.7%, and 67.7%, respectively), meaning that if
the distribution of these factors had been the same across
regions the interregional survival differences would have
been even larger.

Eastern Europe

Infecon
Cardiovascular
Dialysis
Other

Lan America

Asia

Western Europe

North America
0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

Infecon
Cardiovascular
Dialysis
Other
Standardized for Connent

High income

High-middle income

Low-middle income

Low-income

0.0

0.5

1.0

1.5
2.0
2.5
Mortality rate per 100 paent-years

3.0

3.5

4.0

Figure 2. Death-cause speciﬁc mortality rates per 100 patient years per region and per gross national income category.
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1.00

0.05

0.90
0.80
Death

0.46
Cumulave Incidence

0.70
0.60

Alive on PD

0.50
Switch to TX

0.40
0.30

0.43

Switch to HD

0.20
0.10
0.06

0.00
0.0

0.5

1.0

1.5
Time in years

2.0

2.5

3.0

Asia

1.00

Lan America

1.00

0.06

0.80

Cumulave Incidence

Cumulave Incidence

0.07

0.60

0.60
0.40

0.29
0.20

0.80

0.40

0.30
0.20

0.04

0.00

0.07
0.00

0.0

0.5

1.0

1.5

2.0

2.5

3.0

0.0

Time in years

0.5

1.0

1.5

2.0

2.5

3.0

Time in years

Eastern Europe

1.00

0.03
Cumulave Incidence

0.80

0.38
0.60
0.40

Western Europe

1.00

0.09
Cumulave Incidence

0.57

0.60

0.49

0.20

0.80

0.33

0.60

0.57
0.40
0.20

0.04

0.07

0.00

0.00
0.0

0.5

1.0

1.5

2.0

2.5

3.0

0.0

Time in years

0.5

1.0

1.5

2.0

2.5

3.0

Time in years

North America

1.00

Cumulave Incidence

0.02
0.80

0.37
0.60
0.40

0.56

0.20

0.06

0.00
0.0

0.5

1.0

1.5

2.0

2.5

3.0

Time in years

Figure 3. Probability of death, switch to hemodialysis, or receiving a transplant in the total International Pediatric Peritoneal Dialysis
Network cohort per region during 3 years of follow-up assessment. Abbreviations: HD, hemodialysis; PD, peritoneal dialysis; TX,
transplantation.

Discussion
In this study, which was based on a large, worldwide
cohort of children on MPD, the CICR analysis showed a
386

global probability of death on MPD of 5% within 3 years
of follow-up assessment. However, substantial interregional variation exists in patient survival on MPD, as well
as in the causes of death. Our analysis showed that, in
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Figure 4. Probability of death, switch to hemodialysis, or receiving a transplant per income category during 3 years of follow-up
assessment. Abbreviations: HD, hemodialysis; PD, peritoneal dialysis; TX, transplantation.

decreasing order, GNI, choice of modality at start, and BMI
may explain these interregional differences.
Research based on an earlier cohort of the IPPN Registry
already showed that global economic disparities influence
practices and outcomes of MPD in children.15 In this study,
patient survival on MPD was significantly higher in patients
from countries with a GNI exceeding $28,000 (94.1% at 5
years) compared with countries with a GNI of less than
$28,000 (88.7%). In line with our findings, Chesnaye
et al11 showed that there is considerable variation in
mortality rates in children treated with KRT within Europe,
and that macroeconomic factors affected pediatric KRT
survival, even within the developed part of Europe with
the median GNI exceeding $10,000. Intraregional distribution differences in GNI and mortality risk as seen in
Europe may also play a role in other regions, especially in
Asia. Countries such as Singapore and Hong Kong differ
substantially from, for example, India and Pakistan,
particularly with regard to wealth and health expenditure.16,17 Therefore we also divided our cohort based on
national income in addition to geographical location.
Competing risk analyses in these GNI subgroups showed
that lower income is associated with a higher mortality
risk, a higher risk of switching to HD, and a lower probability of receiving a kidney transplant.
Although differences in macroeconomics seem to be
largely responsible for the variance between regions, we
found that other factors, independent from GNI, may also
influence pediatric MPD survival.
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The causes of death also varied between regions. We
found that non–dialysis-related infection was the most
common cause of death in all regions, with the highest
mortality found in Latin America and Eastern Europe.
This may be explained by the significantly higher burden
of communicable diseases in these regions, as was
demonstrated by the Global Burden of Disease study.21
The latter study showed that in countries with a lower
GNI, deaths due to communicable, maternal, neonatal,
and nutritional disease occurred more often. The number
of deaths due to these causes has sharply decreased over
the past decades but remains high in low-income
compared with high-income countries. Another important cause of death was cardiovascular disease. The
mortality rate due to cardiovascular-related death
decreased with increasing GNI. This might be due to the
fact that in wealthier countries more cardiovascular
complications are prevented by an increased use of
antihypertensive drugs and closer surveillance of other
cardiovascular risk factors.22,23
The main strength of this study is the inclusion of MPD
patients from across the globe, which enabled for the first
time a study of the effect of macroeconomic indicators on
survival in children on MPD. In addition, the dataset
contained comprehensive and complete clinical data of
these patients.
A limitation of our study is that online registries such
as the IPPN may suffer from problems with the accuracy
and quality of the data, but several data checks are
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Table 2. Variance and Proportional Change in Variance
Exposure
Baseline model
Region
Macroeconomics
GNI
Patient factors
Age
Sex
Primary kidney disorder
BMI
Comorbidities
Treatment factors
Choice of modality
KRT vintage

Confounders

Variance (SE)

PCV

—

0.24 (0.20)

Reference

None

0.12 (0.13)

−50.1%

GNI, sex
GNI, age
GNI, sex, age
GNI, sex, age, primary kidney disorder, modality,
KRT vintage
GNI, sex, age, primary kidney disorder, modality,
KRT vintage, BMI

0.31
0.23
0.24
0.21

(0.26)
(0.20)
(0.21)
(0.18)

+32.7%
−2.4%
+2.1%
−11.1%

0.40 (0.32)

+67.7%

GNI, age, sex, primary kidney disorder
GNI, age, sex, primary kidney disorder, modality

0.18 (0.17)
0.21 (0.19)

−22.5%
−9.3%

For all exposures separate statistical models were built, including those covariates that fulﬁll the 3 criteria for confounding (see Methods). Abbreviations: BMI, body mass
index; GNI, gross national income; KRT, kidney replacement therapy; PCV, proportional change in variance.

applied to minimize the influence of these issues.
Another limitation is that selection bias may have had an
influence on our findings. It is generally assumed that
survival on MPD is lower in the developing world,
although recent mortality reports are lacking.16,24–26 Our
Kaplan-Meier analysis showed that 3-year overall patient
survival on MPD in the IPPN cohort was 93%. This
overall survival, including patients from both developed
and developing countries, was similar to the 92% survival
found by the US Renal Data System (USRDS), a
population-based kidney disease registry in the United
States that used a rather similar analysis approach,
although there were some subtle differences (ie, no
censoring at switch to HD).4 This suggests at least some
degree of selection bias in the IPPN sample, possibly due
to a higher participation of specialized MPD centers
across the world, which may focus more on MPD patients and adhere better to guidelines. We should, however, keep in mind that the Kaplan-Meier estimates were
only included in the current study for the sake of comparison and are somewhat biased due to the presence of
competing risks.
Comparison of survival as reported in population-based
registries per region shows that survival in the North
American patients in the IPPN cohort is better than survival
in the USRDS: 97% in IPPN versus 92% in USRDS. This
could in part be due to the inclusion of patients aged 18
years in the IPPN, who are excluded in USRDS. It could
also suggest that selection bias was slightly more pronounced in patients from North America. This may explain
the marginal survival difference between North America
and Western Europe in the current study. From Western
Europe a much larger sample was included in the IPPN,
suggesting a greater coverage and thus a better representative sample compared with North America. In line with
this notion, survival in the IPPN Registry was almost
identical to the survival rates observed in the population388

based European Society of Paediatric Nephrology/European Renal Association–European Dialysis and Transplant
Association (ESPN/ERA-EDTA) Registry (95% in IPPN vs
94% in the ESPN/ERA-EDTA Registry using the same age
and sex distribution [M. Bonthuis, personal communication, June 2020]). Selection bias also seemed to play a
role in the poor survival found in Eastern European patients, as the survival in the IPPN was lower than that
reported in the ESPN/ERA-EDTA Registry (89% vs 92%
[M. Bonthuis, personal communication, June 2020]). We
cannot explain this, although center selection and
random variation may play a role. Taken together, this
suggests that our estimation of MPD patient survival is
skewed in both positive and negative directions. As a
consequence, the association between macroeconomics
and MPD survival as we found in this IPPN cohort may
have been diluted, and possibly the true association of
macroeconomics and MPD survival at the population level
may be stronger.
For the purpose of interregional outcome comparisons, population-based studies, such as the recently
launched International Pediatric Nephrology Association
Global Renal Replacement Therapy (IPNA Global RRT)
Registry, are more suitable, provided that contributing
registries have a sufficiently high coverage of patients in
their countries. The IPNA Registry aims to combine all
existing pediatric national renal registries and provide a
platform for countries that do not have such a registry
yet.
In conclusion, this study shows that the overall 3-year
patient survival on pediatric MPD is high, and that
country income is associated with patient survival. On the
other hand, the interpretation of interregional survival
differences as found in this study remains complicated
due to selection bias working in different directions. To
reduce such bias, population-based registries are
warranted.
AJKD Vol 78 | Iss 3 | September 2021

Ploos van Amstel et al
accountability for the overall work by ensuring that questions
pertaining to the accuracy or integrity of any portion of the work
are appropriately investigated and resolved.
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